Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

BACKGROUND: Adjuvant chemotherapy using intraperitoneal (IP) treatment has demonstrated survival benefit over intravenous (IV) therapy alone in patients treated with upfront debulking surgery for advanced stage ovarian cancer. Neoadjuvant chemotherapy followed by interim surgery and adjuvant chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Meghal, Trishala, Dave, Vishangi, Tang, Horace, Kumar, Vivek, Xu, Yiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556590/
https://www.ncbi.nlm.nih.gov/pubmed/31205865
http://dx.doi.org/10.5306/wjco.v10.i5.201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556590/
https://www.ncbi.nlm.nih.gov/pubmed/31205865
http://dx.doi.org/10.5306/wjco.v10.i5.201

Ejemplares similares